Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $163.6 million.

  • Oncology Institute's Liabilities and Shareholders Equity fell 868.61% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.1 million, marking a year-over-year decrease of 1455.18%. This contributed to the annual value of $172.7 million for FY2024, which is 1745.51% down from last year.
  • Per Oncology Institute's latest filing, its Liabilities and Shareholders Equity stood at $163.6 million for Q3 2025, which was down 868.61% from $159.8 million recorded in Q2 2025.
  • Oncology Institute's Liabilities and Shareholders Equity's 5-year high stood at $283.8 million during Q3 2022, with a 5-year trough of $159.8 million in Q2 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $208.0 million, with a median of $206.5 million in 2022.
  • As far as peak fluctuations go, Oncology Institute's Liabilities and Shareholders Equity soared by 20970.03% in 2021, and later plummeted by 2306.15% in 2023.
  • Over the past 5 years, Oncology Institute's Liabilities and Shareholders Equity (Quarter) stood at $203.4 million in 2021, then increased by 28.62% to $261.7 million in 2022, then decreased by 20.04% to $209.2 million in 2023, then decreased by 17.46% to $172.7 million in 2024, then fell by 5.27% to $163.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $163.6 million in Q3 2025, compared to $159.8 million in Q2 2025 and $164.0 million in Q1 2025.